Emmes Publications | Emmes

Search

Show only items where

Author

Type

Term

Year

Keyword

Found 53 results

Author Title Type [ Year

]

Filters: First Letter Of Title is F [Clear All Filters]

2020

Meador, K. J., Pennell, P. B., May, R. C., Van Marter, L., McElrath, T. F., Brown, C., et al.. (2020). Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy. Neurology, 94(14), e1502-e1511. presented at the 2020 04 07. doi:10.1212/WNL.0000000000008687

Hamzabegovic, F., Goll, J. B., Hooper, W. F., Frey, S., Gelber, C. E., & Abate, G.. (2020). Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures. NPJ Vaccines, 5, 6. presented at the 2020. doi:10.1038/s41541-020-0156-y

2019

Paller, C. J., Huang, E. P., Luechtefeld, T., Massett, H. A., Williams, C. C., Zhao, J., et al.. (2019). Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials. Front Med (Lausanne), 6, 122. presented at the 2019. doi:10.3389/fmed.2019.00122

Pidala, J., Martens, M., Anasetti, C., Carreras, J., Horowitz, M., Lee, S. J., et al.. (2019). Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. JAMA Oncol. presented at the 2019 Sep 26. doi:10.1001/jamaoncol.2019.2974

Schonfeld, T. (2019). Finding Common Ground and Advancing Engagement in Citizen Science. Narrat Inq Bioeth, 9(1), 41-45. presented at the 2019. doi:10.1353/nib.2019.0016

Morgello, S., Gensler, G., Sherman, S., Ellis, R. J., Gelman, B. B., Kolson, D. L., et al.. (2019). Frailty in medically complex individuals with chronic HIV. AIDS, 33(10), 1603-1611. presented at the 2019 08 01. doi:10.1097/QAD.0000000000002250

Edun, I., Gay, K., Sheikh, M., Esterlitz, J., Lynch, D., Pandolfo, M., et al.. (2019). Friedreich’s ataxia Common Data Element Review: Updates to the National Institute of Neurological Disorders and Stroke Friedreich’s ataxia (FA) Common Data Element Recommendations: 2018 FA Working Group Review. Retrieved from https://n.neurology.org/content/92/15_Supplement

King, A. A., McKinstry, R. C., Wu, J., Eapen, M., Abel, R., Varughese, T., et al.. (2019). Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. Biol Blood Marrow Transplant, 25(5), e174-e178. presented at the 2019 05. doi:10.1016/j.bbmt.2019.01.008

2017

Korthuis, P. T., Lum, P. J., Vergara-Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., et al.. (2017). Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction, 112(6), 1036-1044. presented at the 2017 Jun. doi:10.1111/add.13753

Nyombayire, J., Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., et al.. (2017). First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis, 215(1), 95-104. presented at the 2017 Jan 01. doi:10.1093/infdis/jiw500

2015

Forcehimes, A. A., Bogenschutz, M., Sharma, G., Wilson, K., & Moyers, M.. (2015). Fidelity Monitoring Model for an MI-Based Brief Intervention. In 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD). presented at the 13/06/2015, Phoenix, AZ. Retrieved from http://www.cpdd.org/

2014

Baden, L. R., Walsh, S. R., Seaman, M. S., Johnson, J. A., Tucker, R. P., Kleinjan, J. A., et al.. (2014). First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis, 210(7), 1052-61. presented at the 2014 Oct 01. doi:10.1093/infdis/jiu217

Baden, L. R., ,, Seaman, M. S., Johnson, J. A., Tucker, R. P., Kleinjan, J. A., et al.. (2014). First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). J Infect Dis, 210, 1052-1061. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24719474

2013

Haberer, J., Mugo, P., Kibengo, F., Mutua, G., van der Elst, E., Kamali, A., et al.. (2013). Factors Influencing Adherence Behavior for Daily and Intermittent Regimens of Pre-Exposure Prophylaxis (PrEP) Among Men Who Have Sex With Men (MSM) in Kenya. In Adherence 2013. presented at the 02/06/2013, Miami, FL. Retrieved from http://www.iapac.org/AdherenceConference/Adherence_2013.html

Alonso, E. M., Martz, K., Wang, D., Yi, M. S., Neighbors, K., Varni, J. W., et al.. (2013). Factors Predicting Health Related Quality of Life in Pediatric Liver Transplant Recipients in the Functional Outcomes Group. Pediatr Transplant, 17, 605-611. presented at the 11/2013. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23902630

Alonso, E. M., Martz, K., Wang, D., Yi, M. S., Neighbors, K., Varni, J. W., & Bucuvalas, J. C.. (2013). Factors predicting health-related quality of life in pediatric liver transplant recipients in the functional outcomes group. Pediatr Transplant, 17(7), 605-11. presented at the 2013 Nov. doi:10.1111/petr.12126

Cohen, M. J., Meador, K. J., Browning, N., May, R., Baker, G. A., Clayton-Smith, J., et al.. (2013). Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years. Epilepsy Behav, 29(2), 308-15. presented at the 2013 Nov. doi:10.1016/j.yebeh.2013.08.001

Cohen, M. J., Meador, K. J., Browning, N., May, R., Baker, G. A., Clayton-Smith, J., et al.. (2013). Fetal Antiepileptic Drug Exposure: Adaptive and Emotional/Behavioral Functioning at Age 6 Years. Epilepsy Behav, 29, 308-315. presented at the 11/2013. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24012508

Meador, K. J., Baker, G. A., Browning, N., Cohen, M. J., Bromley, R. L., Clayton-Smith, J., et al.. (2013). Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol, 12(3), 244-52. presented at the 2013 Mar. doi:10.1016/S1474-4422(12)70323-X

Meador, K. J., Baker, G. A., Browning, N., Cohen, M. J., Bromley, R. L., Clayton-Smith, J., et al.. (2013). Fetal Antiepileptic Drug Exposure and Cognitive Outcomes at Age 6 Years (NEAD Study): A Prospective Observational Study. Lancet Neurol, 12, 244-252. presented at the 03/2013. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23352199

May, R. C. (2013). Finding Your First Industry Job. In International Biometric Society - Eastern North American Region (ENAR). presented at the 10/05/2013, Orlando, FL. Retrieved from http://www.enar.org/

Baden, L. R., Walsh, S. R., Seaman, M. S., Tucker, R. P., Krause, K. H., Patel, A., et al.. (2013). First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis, 207(2), 240-7. presented at the 2013 Jan 15. doi:10.1093/infdis/jis670

Baden, L. R., ,, Seaman, M. S., Tucker, R. P., Krause, K. H., Patel, A., et al.. (2013). First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). J Infect Dis, 207, 240-247. presented at the 01/2013. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed?term=23125444

2012

Tolar, J., Deeg, H. J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., et al.. (2012). Fludarabine-Based Conditioning for Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose De-Escalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels. Biol Blood Marrow Transplant, 18, 1007-1011. presented at the 07/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22546497

Tolar, J., H Deeg, J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., et al.. (2012). Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant, 18(7), 1007-11. presented at the 2012 Jul. doi:10.1016/j.bbmt.2012.04.014

1
2
3
next
last